RecruitingNot ApplicableNCT06026189

Safely Reduce Cystoscopic Evaluations for Hematuria Patients


Sponsor

Erasmus Medical Center

Enrollment

1,100 participants

Start Date

May 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study is looking at whether it is safe to reduce the number of cystoscopy (internal bladder camera) exams for certain patients who have microscopic blood in their urine (called microscopic hematuria). Most of the time, this blood comes from benign causes. Researchers want to know if fewer invasive exams are needed without missing important diagnoses. **You may be eligible if...** - You are a man aged 40 or older, or a woman aged 50 or older - Lab tests have detected at least 3 red blood cells per field in your urine (microscopic hematuria confirmed) **You may NOT be eligible if...** - You have a history of bladder cancer or urinary tract cancer - Your blood in the urine is visible to the naked eye (macroscopic hematuria) - You are or may be pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTurine-first strategy

Only patients with an abnormal urine test result undergo a diagnostic workup, i.e. cystoscopy and upper-tract imaging.


Locations(1)

SeARCH-trial Pijpers

Rotterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06026189


Related Trials